SEC Company Response from Predictive Oncology Inc. (AGPU) (CIK 0001446159) (AGPU) — Nov 15, 2019
Predictive Oncology Inc. (AGPU) (CIK 0001446159)
Date: Nov. 15, 2019 · CIK: 0001446159 · Accession: 0001171843-19-007594
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-234366
Letter
VIA EDGAR Division of Corporation Finance Office of Life Sciences Securities and Exchange Commission Re: Predictive Oncology Inc. Registration Statement on Form S-1 Filed: October 30, 2019 File No.: 333-234366
Dear Mr. Fischer:
Filed herewith is Amendment No. 1 to the Company’s Registration Statement on Form S-1 filed via EDGAR on October 30, 2019 (the “Form S-1”). We are writing to submit the response of Predictive Oncology Inc. (the “Company”) to the comments of the staff (the “Staff”) of the Division of Corporation Finance of the United States Securities and Exchange Commission (the “Commission”) set forth in its comment letter, dated November 13, 2019, relating to the Form S-1. Please note that, for the Staff’s convenience, we have recited the Staff’s comments in italicized type below and have followed the comments with the Company’s response.
Form S-1 filed October 30, 2019
Additional Risk Factor, page 6
1. We note the additional risk factor you have provided addressing your Exclusive Forum Provision under Delaware law. To avoid the possibility of any confusion, please revise sentence two of the risk factor to clarify, if true, that your exclusive forum selection provision does not apply to actions arising under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.
Response: We have clarified the risk factor accordingly, as shown on page 6 of Amendment No. 1.
* * *
Should you have any additional comments or questions, please contact the undersigned at (651) 389-4806 or Martin Rosenbaum, Esq. of Maslon LLP, counsel to the Company, at (612) 672-8326.
Sincerely,
/s/ Bob Myers
Show Raw Text
CORRESP
1
filename1.htm
PREDICTIVE ONCOLOGY INC.
November 15, 2019
VIA EDGAR
Paul Fischer, Esq.
Division of Corporation Finance
Office of Life Sciences
Securities and Exchange Commission
100 F Street NE
Washington, D.C. 20549
Re: Predictive Oncology Inc.
Registration Statement on Form S-1
Filed: October 30, 2019
File No.: 333-234366
Dear Mr. Fischer:
Filed herewith is Amendment No. 1 to the Company’s
Registration Statement on Form S-1 filed via EDGAR on October 30, 2019 (the “Form S-1”). We are writing to submit
the response of Predictive Oncology Inc. (the “Company”) to the comments of the staff (the “Staff”)
of the Division of Corporation Finance of the United States Securities and Exchange Commission (the “Commission”)
set forth in its comment letter, dated November 13, 2019, relating to the Form S-1. Please note that, for the Staff’s convenience,
we have recited the Staff’s comments in italicized type below and have followed the comments with the Company’s response.
Form S-1 filed October 30, 2019
Additional Risk Factor, page 6
1. We note the additional risk factor you have provided addressing your Exclusive
Forum Provision under Delaware law. To avoid the possibility of any confusion, please revise sentence two of the risk factor to
clarify, if true, that your exclusive forum selection provision does not apply to actions arising under the Securities Act of
1933, as amended, or the Securities Exchange Act of 1934, as amended.
Response:
We have clarified the risk factor accordingly, as shown on page 6 of Amendment No. 1.
* * *
1
Should you have any additional comments or questions,
please contact the undersigned at (651) 389-4806 or Martin Rosenbaum, Esq. of Maslon LLP, counsel to the Company, at (612) 672-8326.
Sincerely,
/s/ Bob Myers
Bob Myers
Chief Financial Officer of Predictive Oncology Inc.
cc: Carl Schwartz, Chief Executive Officer, Predictive Oncology Inc.
Martin R. Rosenbaum, Esq., Maslon LLP
2